Absci Corporation (ABSI) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Company Overview - Absci is utilizing generative AI to design antibody-based therapeutics, focusing on this area for the past 4 to 5 years [2] - The company has developed a lab-in-the-loop process to enhance model development, moving beyond just designing molecules in silico to actually producing molecules for clinical advancement [2] Lead Program - The flagship program of Absci is ABS-201, an AI-designed antibody targeting the prolactin receptor, which exhibits strong developability and good half-life [3] - ABS-201 is currently being advanced in a Phase I/IIa study for androgenetic conditions [3]